Genmab A (GMAB) Change in Working Capital (2023 - 2026)

Genmab A's Change in Working Capital history runs 4 years deep, the most recent figure standing at $145.0 million for Q1 2026.

• Quarterly Change in Working Capital fell 52.46% year-over-year to $145.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.2 billion (down 10.25% YoY) and the FY2024 annual result came in at $1.0 billion, down 4.83% from the prior year.
• Change in Working Capital was $145.0 million for Q1 2026 at Genmab A, down from $1.1 billion in the prior quarter.
• Across five years, Change in Working Capital topped out at $1.1 billion in Q3 2025 and bottomed at $145.0 million in Q1 2026.
• A 4-year average of $625.2 million and a median of $609.0 million in 2025 frame the typical range for Change in Working Capital.
• Annual changes were most pronounced in 2025 — Change in Working Capital jumped 65.0% — and 2026, when it slumped 52.46%.
• Genmab A's Change in Working Capital stood at $1.1 billion in 2023, then slipped by 4.83% to $1.0 billion in 2024, then rose by 7.37% to $1.1 billion in 2025, then plunged by 87.08% to $145.0 million in 2026.
• Business Quant data shows GMAB's Change in Working Capital at $145.0 million in Q1 2026, $1.1 billion in Q3 2025, and $609.0 million in Q2 2025.